BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington
November 22, 2016 at 12:05 PM EST
BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company working on regenerative medicine and pluripotent stem cell ...